{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:44Z","timestamp":1786980104661,"version":"build-2736575974"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03361-x","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T07:01:51Z","timestamp":1726297311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management"],"prefix":"10.1007","volume":"316","author":[{"given":"Deesha D.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambika","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnaemeka","family":"Anyanwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen I.","family":"Lo Sicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"issue":"3","key":"3361_CR1","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2133.2005.06218.x","volume":"152","author":"R Sinclair","year":"2005","unstructured":"Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152(3):466\u2013473","journal-title":"Br J Dermatol"},{"issue":"3","key":"3361_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.det.2010.03.011","volume":"28","author":"D Rathnayake","year":"2010","unstructured":"Rathnayake D, Sinclair R (2010) Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 28(3):611\u2013618","journal-title":"Dermatol Clin"},{"issue":"12","key":"3361_CR3","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1111\/jdv.15171","volume":"32","author":"P Suchonwanit","year":"2018","unstructured":"Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S (2018) A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol 32(12):2257\u20132263","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"3361_CR4","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jaad.2021.02.054","volume":"84","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2021","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Pirmez R, Hermosa-Gelbard A et al (2021) Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol 84(6):1644\u20131651","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03361-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T13:04:10Z","timestamp":1729861450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03361-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":4,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3361"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03361-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"NYU Langone Health IRB Approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval"}},{"value":"Dr Lo Sicco has been an investigator for Regen Lab and is an investigator for Pfizer. Dr. Lo Sicco is a consultant for Pfizer and Aquis. Dr. Shapiro is an investigator and consultant for Pfizer and is a consultant for Lilly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"622"}}